Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Yun-Fei Zhu

Scott Struthers

Stephen F. Betz

Crinetics Pharmaceuticals, Inc.

Nuri Clinic offers access to advanced peptide therapy and holistic health services, including live support from medical professionals.

Nuri Clinic

This place is about more than a pharmaceutical career. It’s about making a real difference in the lives of patients. That’s why we’re here. That’s why you should maybe think about being here, too.Our mission is to build the leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives. Working to accomplish this mission is how we bring our vision to life. For us, that vision is the best possible therapeutics available to all patients with diseases of the endocrine system. We love how that sounds. And we really can’t wait to know how it feels.

Metric
Company Name	Crinetics Pharmaceuticals, Inc.	Nuri Clinic
Symbol	CRNX
MSH ID	COM:CRINETICS	COM:NURICLINIC
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Health and Wellness
Country	US	US
Stage
Employee Count	290
Website	crinetics.com	nuriclinic.com
LinkedIn	crinetics-pharmaceuticals
Founders

Metric
Market Cap	4.01B
Enterprise Value
Monthly Web Traffic	29.06K
Web Traffic Growth	-0.40
Valuation
Raised Capital	500M

Metric
Revenue	4.01M
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.92M
EBITDA	-221.51M
Operating Income	-222.61M
Net Income	-214.53M
EPS	-3.69
Diluted EPS	-3.69
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.67
Operating Profit Margin	-55.47
EBITDA Margin	-55.20
Net Profit Margin	-52.96
Return on Equity	2.98
Return on Assets	-0.24
Return on Capital Employed	-0.27

COM:CRINETICS

Crinetics Pharmaceuticals

Last Close

57.03

22/11 21:00

Market Cap

4.01B

Beta: -

Volume Today

1.02M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-10.94
P/B Ratio	-3.59
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	3.84K
EV Multiple	-14.83

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle	1.75K
Cash Conversion Cycle	-493.80
Asset Turnover	0.01

Metric
Operating Cash Flow	-166.31M
Free Cash Flow	-171.00M
Cash Flow to Debt	-3.22
Operating Cash Flow/Sales	-41.44
Free Cash Flow Yield	-0.05

Metric
Cash & Equivalents	54.90M
Accounts Receivable	14.65M
Inventory
Goodwill
Debt to Capitalization	0.09
Debt to Assets	0.08
Current Ratio	14.23
Quick Ratio	17.72

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	5.55
R&D to Revenue	33.87
SG&A to Revenue	11.07